The Danish TPE compounder Melitek has proudly announced that the company has obtained the Renewable Energy Certificate by switching all its energy consumption to wind power. The company has signed an agreement, switching all its energy consumption to renewable supply according to the RECS (Renewable Energy Certificate System). The agreement is entered with SEAS-NVE who will supply Melitek 100 % green energy produced from wind power.
“Melitek would like to contribute to the switch to renewable energy and take an active role in reducing CO2-emission”, says managing director Kim Laursen. “It has always been in our company’s DNA to offer medical grade plastics with good environmental profile, and as such the switch to green energy supply marks a milestone in our strive to manufacture our products under the best conditions”, he continues.
Christian Ellekær, Key Account Manager from SEAS-NVE presented the Renewable Energy Certificate, stated “Melitek’s switch to wind power energy equals a total CO2 saving of almost 1,000 t CO2 annual with the current consumption.”
“It makes totally sense for us that we ensure our polyolefin based products which are designed for easy recycling, and that often replaces polymers with poor eco-profile such as PVC and various engineering resins, are now produced using solely wind power”, concludes Jesper Laursen, business director of Melitek.
Earlier this year in February the company brought three siloes for high volume resin supply into operation. The company said that this measure will have positive impact on the environment by reducing >200,000 plastic bags and optimising road transport by larger delivery quantities. Furthermore the siloes further improve work flows and bring more warehouse capacity to support the company’s on-going growth.
Melitek specialises in elastomer and polymer compounds designed for the healthcare market and manufactured under ISO 13485:2016. The products are sold globally into pharmaceutical packaging, medical devices and diagnostic applications and are in compliance to ISO 10993, European and US Pharmacopeias. The privately held company, established in 1979, produces exclusively in Alslev, Denmark. Capacity is 25,000 t/y.